A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.

Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial. 

The company will imminently start its third pivotal trial of PF-08634404.

An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.

A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.

But first it will need to identify the optimal dose in first-line small-cell lung cancer.

Global data are in the same ballpark as Chinese results presented earlier this year.

Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.

Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.